Bellevue Group’s AC Immune ACIU Stock Holding History

Bellevue Group’s Portfolio ACIU Stock Details ACIU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-139,000	Closed	-$933K	–	192
2021 Q3	$933K	Buy	+139,000	New	+$995K	0.01%	158

Other funds holding ACIU

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

LOAMS

Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Bellevue Group's ACIU Position: Q4 2021 in Review

Bellevue Group sold out of AC Immune (ACIU) in Q4 2021, closing a stake of 139,000 shares — an estimated $933K sold.

Bellevue Group first reported a position in ACIU in Q3 2021 and held it in 1 quarter. The position peaked at $933K in Q3 2021. 44 funds tracked by Wall St. Rank hold ACIU as of Q4 2021.

Bellevue Group reported no remaining AC Immune position as of Q4 2021 after selling out during the quarter.
Bellevue Group sold 139,000 AC Immune shares in Q4 2021, an estimated $933K.
Bellevue Group first reported a position in AC Immune in Q3 2021 and held it in 1 quarter.
Bellevue Group's AC Immune position peaked at $933K in Q3 2021.
44 funds tracked by Wall St. Rank held AC Immune as of Q4 2021.

Based on Bellevue Group's 13F filing for Q4 2021, filed 10 Feb 2022.